Our Mission
Quintessence Biosciences is working to improve the lives of cancer patients by developing new drugs based on EVade Ribonuclease technologies.
Spotlight
Lead Candidate, QBI-139
A Phase I trial of QBI-139 in cancer patients
with solid tumors is ongoing at the University of Wisconsin
Comprehensive Cancer Center (UWCCC)
in Madison and The University of Texas M. D. Anderson Cancer Center in Houston, Texas.
Information about the trial can be found at www.clinicaltrials.gov
(Clinical Trials.gov Identifier: NCT00818831).
Potential enrollees can contact the UWCCC Cancer
Connect (800-622-8922; 608-262-5223; uwccc@uwccc.wisc.edu) or the M.D. Anderson Cancer Center (askMDAnderson at 1-877-MDA-6789; 713-792-1160) for
information. Quintessence Biosciences
will not directly enroll patients. |
Latest News
4.19.12 Quintessence Biosciences Selected for Buzz of BIO at 2012 BIO International Convention (PDF)
Quintessence Biosciences has been chosen to participate in the Buzz of BIO, which allows industry leaders to select biotechnology companies to present at the Business Forum at the 2012 BIO International Convention.
4.12.12 Quintessence Biosciences Announces Election of Walter Dewey to Board of Directors (PDF)
Quintessence Biosciences today announced that Mr. Walter Dewey was elected by shareholders to join the Company’s Board of Directors. In addition to election of the Board of Directors, the annual meeting included a report from management on the progress of the Phase I trial of lead ribonuclease candidate QBI-139.
3.30.12 Quintessence Biosciences Presents Results for Combination Studies of Clinical Stage Ribonuclease QBI-139 at AACR Meeting (PDF)
Quintessence today announced that pre-clinical combination study data for QBI-139, a first in class drug in a Phase I clinical trial, will be presented at the American Association for Cancer Research annual meeting.
|
